NCT05378360 - DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

December 5, 2023

Study Completion Date

December 28, 2023

Conditions

Rash Acneiform

Interventions

BIOLOGICAL

DWP708

Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days

Trial Locations (1)

49201

Dong-A University Hospital, Busan